咪唑并[1,5-A]吡啶并[2,3-E]吡嗪-4(5H)-酮 | 240815-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶吡嗪类
• 中文名称: 咪唑并[1,5-A]吡啶并[2,3-E]吡嗪-4(5H)-酮
• 中文别名: 咪唑并[1,5-a]吡啶并[2,3-E]吡嗪-4(5H)-酮
• 英文名称: imidazo[1,5-a]pyrido[2,3-e]pyrazine-6(5H)-one
• 英文别名: Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one；2,4,8,10-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,10,12-pentaen-7-one
• CAS: 240815-61-6
• 化学式: C₉H₆N₄O
• 分子量: 186.173
• InChiKey: QQFFWRBKCBSJDB-UHFFFAOYSA-N

物化性质

• 沸点：
  320.7±30.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  咪唑并[1,5-A]吡啶并[2,3-E]吡嗪-4(5H)-酮 在 三氯氧磷 作用下， 生成 4-Chloroimidazo[1,5-a]pyrido[2,3-e]pyrazine
  参考文献：
  名称：

  Imidazoquinoxaline Src-Family Kinase p56^Lck Inhibitors:  SAR, QSAR, and the Discovery of (S)-N-(2-Chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a Potent and Orally Active Inhibitor with Excellent in Vivo Antiinflammatory Activity

  摘要：

  A series of novel anilino 5-azaimidazoquinoxaline analogues possessing potent in vitro activity against p56(Lck) and T cell proliferation have been discovered. Subsequent SAR studies led to the identification of compound 4 (BMS-279700) as an orally active lead candidate that blocks the production of proinflammatory cytokines (IL-2 and TNFalpha) in vivo. In addition, an expanded set of imidazoquinoxalines provided several descriptive QSAR models highlighting the influence of significant steric and electronic features. The H-bonding (Met319) contribution to observed binding affinities within a tightly congeneric series was found to be significant.

  DOI：

  10.1021/jm030217e
• 作为产物：
  描述：

  5-[(2,4-Dimethoxyphenyl)methyl]imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-on 在 三氟乙酸 、 碳酸氢钠 作用下， 以 水 为溶剂， 反应 3.0h， 生成 咪唑并[1,5-A]吡啶并[2,3-E]吡嗪-4(5H)-酮
  参考文献：
  名称：

  HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS

  摘要：

  公开号：

  EP1066286B1

文献信息

• ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP2051978A2

  公开（公告）日：2009-04-29
• US5990109A
  申请人：——

  公开号：US5990109A

  公开（公告）日：1999-11-23
• [EN] ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] DÉRIVÉS D'ACÉTAMIDES UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA SÉROTONINE 5-HT2A UTILISÉS POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À CE RÉCEPTEUR
  申请人：ARENA PHARM INC

  公开号：WO2007136875A2

  公开（公告）日：2007-11-29

  [EN] The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT_2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT_2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.
  [FR] La présente invention concerne certains composés représentés par la formule (1a) ainsi que des compositions pharmaceutiques les contenant, lesquels modulent l'activité du récepteur de la sérotonine 5-HT_2A. Les composés et les compositions pharmaceutiques susmentionnés sont destinés à des méthodes utiles pour traiter l'agrégation plaquettaire, la coronaropathie, l'infarctus du myocarde, l'accident ischémique transitoire, l'angine, l'accident vasculaire cérébral, la fibrillation auriculaire, la coagulation sanguine, l'asthme ou l'un de ses symptômes, l'agitation ou l'un de ses symptômes, les troubles du comportement, la psychose induite par les médicaments, la psychose avec excitation, le syndrôme de Tourette, le trouble maniaque, la psychose organique ou non spécifiée, le trouble psychotique, la psychose, la schizophrénie aigue, la schizophrénie chronique, la schizophrénie non spécifiée, et les troubles apparentés, les troubles du sommeil, les troubles liés au diabète, la leucoencéphalopathie multifocale progressive et les troubles similaires. Cette invention concerne également des méthodes utiles pour le traitement de troubles associés au récepteur de la sérotonine 5-HT_2A conjointement avec d'autres agents pharmaceutiques administrés séparément ou ensemble.
• Imidazoquinoxaline Src-Family Kinase p56^Lck Inhibitors:  SAR, QSAR, and the Discovery of (<i>S</i>)-<i>N</i>-(2-Chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-<i>a</i>]pyrido[3,2-<i>e</i>]pyrazin-6-amine (BMS-279700) as a Potent and Orally Active Inhibitor with Excellent in Vivo Antiinflammatory Activity
  作者：Ping Chen、Arthur M. Doweyko、Derek Norris、Henry H. Gu、Steven H. Spergel、Jagabundhu Das、Robert V. Moquin、James Lin、John Wityak、Edwin J. Iwanowicz、Kim W. McIntyre、David J. Shuster、Kamelia Behnia、Saeho Chong、Henry de Fex、Suhong Pang、Sydney Pitt、Ding Ren Shen、Sara Thrall、Paul Stanley、Octavian R. Kocy、Mark R. Witmer、Steven B. Kanner、Gary L. Schieven、Joel C. Barrish

  DOI：10.1021/jm030217e

  日期：2004.8.1

  A series of novel anilino 5-azaimidazoquinoxaline analogues possessing potent in vitro activity against p56(Lck) and T cell proliferation have been discovered. Subsequent SAR studies led to the identification of compound 4 (BMS-279700) as an orally active lead candidate that blocks the production of proinflammatory cytokines (IL-2 and TNFalpha) in vivo. In addition, an expanded set of imidazoquinoxalines provided several descriptive QSAR models highlighting the influence of significant steric and electronic features. The H-bonding (Met319) contribution to observed binding affinities within a tightly congeneric series was found to be significant.
• HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1066286B1

  公开（公告）日：2009-04-29